[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"d413d963-d011-4e09-b546-c83cb27d35a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02159950","created_at":"2021-01-18T10:03:14.468Z","updated_at":"2024-07-02T16:35:49.478Z","phase":"Phase 2","brief_title":"Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT02159950","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T) • tasquinimod (ABR-215050)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2023-04-27"},{"id":"97e655f1-4ba9-4ef3-8071-5589520a47b8","acronym":"NCI-2014-00318","url":"https://clinicaltrials.gov/study/NCT01804465","created_at":"2021-01-18T07:59:42.271Z","updated_at":"2025-02-25T14:34:03.803Z","phase":"Phase 2","brief_title":"Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer","source_id_and_acronym":"NCT01804465 - NCI-2014-00318","lead_sponsor":"University of California, San Francisco","biomarkers":" PSAP","pipe":"","alterations":" ","tags":["PSAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/22/2014","start_date":" 04/22/2014","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 08/31/2020","study_completion_date":" 08/31/2020","last_update_posted":"2021-08-18"},{"id":"9bf8f907-2a84-42d2-9dda-4b4d048f096a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01833208","created_at":"2021-01-18T08:09:25.594Z","updated_at":"2024-07-02T16:36:26.892Z","phase":"","brief_title":"Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T","source_id_and_acronym":"NCT01833208","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 07/03/2013","start_date":" 07/03/2013","primary_txt":" Primary completion: 08/06/2018","primary_completion_date":" 08/06/2018","study_txt":" Completion: 01/23/2021","study_completion_date":" 01/23/2021","last_update_posted":"2021-08-05"},{"id":"9192c317-9830-4f24-91e8-9c91a8ad0583","acronym":"","url":"https://clinicaltrials.gov/study/NCT02463799","created_at":"2021-01-18T11:49:25.358Z","updated_at":"2025-02-25T17:22:48.447Z","phase":"Phase 2","brief_title":"Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC","source_id_and_acronym":"NCT02463799","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IFNG • ICAM1","pipe":"","alterations":" ","tags":["IFNG • ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xofigo (radium Ra-223 dichloride) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/22/2016","start_date":" 02/22/2016","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 12/12/2019","study_completion_date":" 12/12/2019","last_update_posted":"2021-07-08"},{"id":"477d5fbc-6085-4cb2-bdc6-2d42d80ca8fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01706458","created_at":"2021-01-18T07:26:01.412Z","updated_at":"2024-07-02T16:36:28.940Z","phase":"Phase 2","brief_title":"Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer","source_id_and_acronym":"NCT01706458","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CSF2 • GZMB","pipe":"","alterations":" ","tags":["CSF2 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T) • MVI-816"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/20/2013","start_date":" 05/20/2013","primary_txt":" Primary completion: 06/12/2017","primary_completion_date":" 06/12/2017","study_txt":" Completion: 08/13/2020","study_completion_date":" 08/13/2020","last_update_posted":"2021-06-18"},{"id":"f6893cfd-4fd6-431c-866a-8acf5ad99b15","acronym":"","url":"https://clinicaltrials.gov/study/NCT03329742","created_at":"2021-06-23T19:53:57.639Z","updated_at":"2024-07-02T16:36:32.691Z","phase":"","brief_title":"Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer","source_id_and_acronym":"NCT03329742","lead_sponsor":"Indiana University","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 12/19/2017","start_date":" 12/19/2017","primary_txt":" Primary completion: 10/21/2019","primary_completion_date":" 10/21/2019","study_txt":" Completion: 05/05/2020","study_completion_date":" 05/05/2020","last_update_posted":"2021-03-29"},{"id":"dd33b34c-fa94-48d0-9b99-6201650c2301","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560923","created_at":"2021-01-18T06:36:45.368Z","updated_at":"2024-07-02T16:36:46.704Z","phase":"Phase 2","brief_title":"Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer","source_id_and_acronym":"NCT01560923","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e indoximod (NLG8189) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 12/12/2018","primary_completion_date":" 12/12/2018","study_txt":" Completion: 12/12/2018","study_completion_date":" 12/12/2018","last_update_posted":"2020-04-03"},{"id":"24fdc4a9-618c-4a35-93cc-2452df370078","acronym":"","url":"https://clinicaltrials.gov/study/NCT02036918","created_at":"2021-01-18T09:20:54.557Z","updated_at":"2024-07-02T16:36:47.173Z","phase":"Phase 1","brief_title":"Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT02036918","lead_sponsor":"Duke University","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 02/06/2019","primary_completion_date":" 02/06/2019","study_txt":" Completion: 02/06/2019","study_completion_date":" 02/06/2019","last_update_posted":"2020-03-31"},{"id":"ea774ee2-dd2b-414c-a96d-08591fa7b0fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02456571","created_at":"2021-01-18T11:47:06.434Z","updated_at":"2024-07-02T16:36:58.289Z","phase":"","brief_title":"CTC Immune Checkpoint","source_id_and_acronym":"NCT02456571","lead_sponsor":"Duke University","biomarkers":" PD-L1 • CD276 • PD-L2","pipe":" | ","alterations":" PD-L2 expression","tags":["PD-L1 • CD276 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 06/13/2019","primary_completion_date":" 06/13/2019","study_txt":" Completion: 06/13/2019","study_completion_date":" 06/13/2019","last_update_posted":"2019-07-09"},{"id":"2c3c4ed1-ed2b-4f94-b7a4-a27500e532a2","acronym":"STAMP","url":"https://clinicaltrials.gov/study/NCT01487863","created_at":"2021-01-18T06:13:13.453Z","updated_at":"2024-07-02T16:37:01.587Z","phase":"Phase 2","brief_title":"Concurrent vs. Sequential Sipuleucel-T \u0026 Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT01487863 - STAMP","lead_sponsor":"Dendreon","biomarkers":" ICAM1","pipe":"","alterations":" ","tags":["ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2019-03-19"},{"id":"df7b630e-ab5a-4d20-8603-2a3d538cbd9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02232230","created_at":"2021-01-18T10:28:22.786Z","updated_at":"2024-07-02T16:37:04.035Z","phase":"","brief_title":"A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T","source_id_and_acronym":"NCT02232230","lead_sponsor":"GenesisCare USA","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 06/05/2018","primary_completion_date":" 06/05/2018","study_txt":" Completion: 06/05/2018","study_completion_date":" 06/05/2018","last_update_posted":"2019-01-09"},{"id":"191da7f5-edb6-463a-a59a-a983b6c6378f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01832870","created_at":"2021-01-18T08:09:16.755Z","updated_at":"2024-07-02T16:37:18.514Z","phase":"Phase 1","brief_title":"Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer","source_id_and_acronym":"NCT01832870","lead_sponsor":"Prostate Oncology Specialists, Inc.","biomarkers":" PSAP","pipe":"","alterations":" ","tags":["PSAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-08-24"},{"id":"07290b42-fecd-4d59-8d89-3c17f5f0e7a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01431391","created_at":"2021-01-18T05:54:50.916Z","updated_at":"2024-07-02T16:37:21.706Z","phase":"Phase 2","brief_title":"Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer","source_id_and_acronym":"NCT01431391","lead_sponsor":"Dendreon","biomarkers":" IFNG • ICAM1","pipe":"","alterations":" ","tags":["IFNG • ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-05-30"},{"id":"1bd5f8f0-3e44-48ee-b25c-d686af725293","acronym":"ProACT","url":"https://clinicaltrials.gov/study/NCT00715078","created_at":"2021-01-18T02:40:35.437Z","updated_at":"2024-07-02T16:37:21.832Z","phase":"Phase 2","brief_title":"To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen","source_id_and_acronym":"NCT00715078 - ProACT","lead_sponsor":"Dendreon","biomarkers":" ICAM1","pipe":"","alterations":" ","tags":["ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 05/01/2015","study_completion_date":" 05/01/2015","last_update_posted":"2017-05-23"}]